-- 
GDF Suez, Rhodia, Sanofi, Transgene: French Equity Preview

-- B y   M a r k   D e e n
-- 
2011-09-07T04:00:01Z

-- http://www.bloomberg.com/news/2011-09-06/gdf-suez-rhodia-sanofi-transgene-french-equity-preview.html
The following is a list of companies
whose stocks may have unusual price changes in Paris. Symbols
are in parentheses after company names and prices are from the
last close.  France’s  CAC 40 Index (CAC)  fell 1.1 percent to 2,965.64. The
broader SBF 120 Index shed 1.1 percent to 2,277.78.  Biomerieux (BIM)  SA: The maker of tests for HIV and
hepatitis said net income rose 3.7 percent to 75 million euros
($105 million) in the first half and operating income climbed
8.6 percent to 119 million euros. The company expects organic
sales growth of about 5 percent this year. The shares fell 0.6
percent to 72 euros.  GDF Suez (GSZ)  : President and Vice-Chairman Jean-
Francois Cirelli laid out new plans for the company’s European
energy division to employees, La Lettre de L’Expansion reported.
The shares declined 2.1 percent to 19.63 euros.  Rhodia SA (RHA)  :  Fitch Ratings  raised the chemicals
company’s debt to BBB+ from BB and assigned a stable outlook.
The shares gained 0.1 percent to 31.54 euros.  Sanofi (SAN FP): Chief Executive Officer Chris Viehbacher
said he is comfortable with the drugmaker’s current business mix
and said he is optimistic about the prospects for the company
going into the 2012-2015 period. The shares climbed 1.7 percent
to 48.88 euros.  Transgene SA (TNG)  : The developer of vaccines and cancer
said its net loss widened to 17.7 million euros in the first
half from 14.5 million euros a year earlier. Sales rose to 8.1
million euros from 7.3 million euros. The shares fell 1.8
percent to 9.23 euros.  To contact the reporters on this story:
Mark Deen in Paris at 
 markdeen@bloomberg.net   To contact the editor responsible for this story:
Vidya Root in Paris at 
 vroot@bloomberg.net  